查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1875920

全球人类乳突病毒 (HPV) 检测市场

Human Papillomavirus (HPV) Testing
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 173 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

全球人类乳突病毒（HPV）检测市场预计到2030年将达到18亿美元

全球人类乳突病毒 (HPV) 检测市场预计在 2024 年达到 13 亿美元，预计到 2030 年将达到 18 亿美元，在分析期（2024-2030 年）内复合年增长率 (CAGR) 为 6.2%。本报告分析的细分市场之一「医院和诊所」预计将以 6.0% 的复合年增长率成长，并在分析期结束时达到 9.194 亿美元。 「诊断中心」细分市场预计在分析期间将以 6.9% 的复合年增长率成长。

美国市场规模估计为3.527亿美元，而中国市场预计将以5.8%的复合年增长率成长。

预计到2024年，美国乳突病毒（HPV）检测市场规模将达3.527亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到2.845亿美元，2024年至2030年的复合年增长率（CAGR）为5.8%。其他值得关注的区域市场分析包括日本和加拿大，预计在分析期间内，这两个国家的复合年增长率分别为5.8%和5.1%。在欧洲，德国预计复合年增长率约为5.1%。

全球人类乳突病毒（HPV）检测市场－主要市场趋势与驱动因素概述

人类乳突病毒（HPV）检测能否成为预防子宫颈癌、改善女性健康的关键？

人类乳突病毒 (HPV) 检测是女性健康促进计画的基石，但为何它对预防子宫颈癌和改善整体健康状况如此重要？ HPV 是世界上最常见的性行为感染传染病，某些病毒株与子宫颈癌以及其他癌症（如咽癌、肛门癌和外阴癌）的发生直接相关。 HPV 检测可以识别出可能导致这些癌症的高风险 HPV 类型，从而实现早期诊断和治疗。

HPV检测的意义在于它能够在细胞癌变之前很久就检测到高风险感染。透过HPV检测早期发现高风险族群，可以及时采取适当的干预措施，例如额外的诊断程序或疫苗接种等预防措施，从而预防子宫颈癌的发生。 HPV检测与常规巴氏抹片检查相结合，在降低子宫颈癌发生率和改善女性健康方面发挥重要作用。随着人们对HPV在癌症发生发展中的作用认识不断提高，广泛开展HPV检测已成为预防该病毒相关严重后果的重要公共卫生措施。

人类乳突病毒（HPV）检测技术取得了哪些进展？

技术进步显着提高了HPV检测的敏感度、准确性和普及性，使其成为更有效的癌症预防和筛检工具。其中一个最重要的进展是分子诊断技术的引入，例如聚合酵素链锁反应（PCR）检测，该技术能够高精度地检测HPV DNA。基于PCR的检测可以识别特定的HPV株，使临床医生能够区分高风险型和低危险型HPV。这种更高的特异性使得风险评估更加准确，并确保高风险族群得到适当的后续照护。

自动化检测系统的引入简化了HPV检测流程，降低了人为误差的可能性，并提高了临床效率。自动化平台能够快速、统一地处理大量检体，使医疗机构更容易将HPV检测纳入常规筛检计画。这些进步有助于提高HPV检测的可近性，即使在资源匮乏、人工处理困难的地区也是如此。

结合HPV检测和传统巴氏抹片检查（细胞学检查）的联合检测已被证实是子宫颈癌筛检的有效策略。联合检测使医护人员能够同时筛检异常子宫颈细胞和高危险型HPV，进而提高筛检计画的准确性。这种双重筛检方法提高了子宫颈癌前病变的检出率，并有助于更早识别子宫颈癌高风险女性。

另一项重要的技术进步是开发了HPV自采集检测方法，使人们能够在家中自行采集HPV样本。自采集试剂盒包含采集阴道拭子所需的说明和设备，采集的样本随后会被送往检测实验室。这项创新扩大了HPV检测的覆盖范围，使那些难以获得传统医疗服务的群体，例如居住在偏远地区或不愿接受临床检测的人群，也能获得检测服务。研究表明，自采集检体的准确性几乎与医护人员采集的检体相当，使其成为提高HPV筛检普及率的一种很有前景的工具。

数位健康工具的进步也促进了HPV检测的改进。行动应用程式和线上平台帮助人们追踪筛检计画、接收检测结果，并取得HPV和子宫颈癌预防的教育资源。这些数位工具提高了患者的参与度，使人们更容易了解自身健康状况并积极主动地进行健康管理。

液基细胞学（LBC）是HPV检测的另一项改进。与依赖玻片的传统巴氏抹片检查不同，LBC将细胞悬浮于液体中，从而提供更全面、更清晰的样本。此方法不仅提高了异常细胞检出的准确性，而且允许在同一样本上进行HPV检测，从而提高了筛检效率。 LBC已广泛应用于子宫颈癌筛检计画中，有助于减少假阴性结果，并能更早识别出HPV相关异常的女性。

为什么人类乳突病毒（HPV）检测对子宫颈癌预防和公共卫生至关重要？

HPV检测对于子宫颈癌的预防至关重要，因为它能够及早发现高危险型HPV感染，而高危险型HPV感染是子宫颈癌的主要致病因子。透过在子宫颈发生癌变或癌前病变之前识别感染者，HPV检测为早期疗育提供了机会，包括加强后续观察、后续检测以及对异常细胞进行治疗。这种早期发现对于降低子宫颈癌的发生率至关重要，而子宫颈癌也是最可预防的癌症之一，可以透过适当的筛检和疫苗接种来预防。

子宫颈癌是一个缓慢发展的过程，通常始于子宫颈细胞的癌前病变。 HPV检测可以检测出最有可能导致这些病变的高风险病毒株，从而在巴氏抹片检查发现病变之前就发现它们。这使得医护人员能够更密切后续观察患者，并降低子宫颈癌未被发现的风险。 HPV检测对于30岁以上的女性尤其重要，因为在这个年龄段，持续性HPV感染更容易导致子宫颈癌。

HPV检测对公共卫生至关重要，有助于降低HPV相关癌症的整体负担。除子宫颈癌外，高危险型HPV也与其他癌症有关，包括肛门癌、口咽癌（喉癌）和阴茎癌。虽然子宫颈癌筛检是HPV检测最成熟的应用，但目前仍在研究如何将HPV检测应用于其他癌症的筛检，尤其是在高风险族群中。

HPV检测在预防保健中的作用不仅限于诊断。 HPV检测在指导疫苗接种工作中也扮演重要角色。 HPV人类乳突病毒(HPV)疫苗的引入显着降低了高危险型HPV感染率和子宫颈癌发生率。然而，由于并非所有人都接种了疫苗，且疫苗在接触HPV病毒前接种最为有效，因此仍需定期进行检测，以发现未接种疫苗或部分接种疫苗人群的感染情况。 HPV检测有助于确定接种疫苗后个体是否仍感染高危险型HPV，从而确保他们获得必要的后续照护。

将HPV检测纳入更广泛的子宫颈癌筛检项目，并提高了全球预防性护理的有效性。子宫颈癌仍然是许多国家女性死亡的主要原因之一，尤其是在医疗资源匮乏的地区。与单独的巴氏抹片检查相比，HPV检测在检测癌前病变方面更加灵敏可靠，即使在资源匮乏的环境中也能帮助识别高风险族群。 HPV自取样检测的引入进一步扩大了筛检的覆盖范围，无需面诊，有助于消除农村和医疗服务不足地区的障碍。

虽然男性接受常规HPV检测的普及程度不如女性，但高风险族群（例如男男性行为者）对HPV相关癌症的认识正在不断提高。由于HPV感染是这些族群的重要风险因素，HPV检测越来越多地被用于肛门癌筛检。透过将HPV检测推广到女性以外的其他族群，医疗系统有望进一步降低整个人群中HPV相关癌症的发生率。

哪些因素正在推动人类乳突病毒（HPV）检测市场的成长？

HPV检测市场的成长受多种因素驱动，包括HPV感染率的上升趋势、子宫颈癌预防意识的增强以及检测技术的进步。其中一个主要驱动因素是人们越来越意识到早期检测在预防HPV相关癌症的重要性。随着公共卫生宣传活动不断强调定期筛检和疫苗接种的益处，越来越多的人将HPV检测纳入日常医疗保健计划。这增加了对HPV检测服务的需求，尤其是在已建立子宫颈癌筛检计画的国家。

市场成长也得益于全​​球疫苗接种计画的扩展，尤其是人类乳突病毒(HPV)疫苗的推广。随着疫苗接种覆盖率的提高，HPV检测对于监测疫苗的长期有效性以及识别未接种或部分接种人群中的感染情况仍然至关重要。在已开展人类乳突病毒(HPV)疫苗疫苗接种计画的国家，HPV检测在追踪疫苗对HPV感染率的影响以及指导公共卫生政策方面发挥关键作用。

HPV检测技术的进步提高了检测的准确性、普及性和效率，进一步推动了市场需求。基于PCR的检测、自动化检测平台和自采集试剂盒等创新技术使HPV检测更加便捷可靠，扩大了其在临床和家庭环境中的应用。特别是自采集HPV检测的发展，随着更多国家采用这些方法，预计将持续推动市场成长，扩大筛检覆盖范围，尤其是在服务不足的地区。

政府旨在降低子宫颈癌发生率的主导和公共卫生计画也是推动市场成长要素的关键因素。在许多地区，医疗卫生系统正从传统的子宫颈癌子宫颈抹片检查—过渡到HPV检测，后者在检测高风险感染方面具有更高的灵敏度。尤其是在医疗卫生系统较为发达的国家，预计HPV筛检在国家筛检计画中的应用将显着增加，从而进一步推动市场成长。

对个人化医疗日益增长的需求也推动了HP​​V检测市场的成长。随着精准医疗的重要性日益凸显，人们对考虑个人独特风险因素的个人化筛检和预防策略越来越感兴趣。 HPV检测透过识别高风险族群并据此制定个人化的后续照护方案，为子宫颈癌筛检提供了更个人化的方法。随着医疗保健系统朝向更个人化的照护模式发展，这一趋势预计将持续下去，因为像HPV筛检这样的检测在疾病预防中发挥关键作用。

除子宫颈癌外，HPV相关癌症的增加也是推动市场成长的因素之一。虽然HPV检测的主要目标是子宫颈癌，但该病毒也会导致其他癌症，例如肛门癌、口咽癌和阴茎癌。随着人们对这些HPV相关癌症的认识不断提高，尤其是在高风险族群中，预计除传统子宫颈癌筛检外，对HPV检测的需求将会扩大，为市场创造新的成长机会。

由于技术进步、公众健康意识的提高以及HPV检测被纳入国家筛检计划，HPV检测市场预计将持续扩张。随着医疗保健系统日益重视早期发现和预防性护理，HPV检测仍将是降低HPV相关癌症发生率和改善全球健康状况的关键工具。

部分：

依最终使用者（医院/诊所、诊断中心、研究机构）划分

受访公司范例

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Arbor Vita Corporation
  • Becton, Dickinson & Company
  • Cepheid, Inc.
  • Daan Gene Co., Ltd.
  • Diagcor Bioscience Incorporation Ltd.
  • Enzo Biochem, Inc.
  • F. Hoffmann-La Roche AG
  • Fujirebio US, Inc.
  • Greiner Bio-One International GmbH
  • Hologic, Inc.
  • Hybribio Limited
  • Medical & Biological Laboratories Co. Ltd.
  • Norgen Biotek Corporation
  • Promega Corporation
  • Qiagen NV
  • Seegene, Inc.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • Zytovision GmbH

人工智慧集成

我们正在利用检验的专家内容和人工智慧工具来变革市场和竞争情报。

Market Glass, Inc. 没有采用查询LLM 或产业专用的SLM 的常见做法，而是建立了一个由世界各地领域专家精心策划的内容库，其中包括视频转录、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

在最新发布的报告中，Market Glass, Inc. 将关税对地理市场的影响纳入考量，并根据公司总部所在国、製造地以及进出口（成品和OEM产品）情况，预测企业竞争格局的变化。这种复杂多变的市场现实将对竞争对手产生多方面的影响，包括销货成本增加、盈利下降和供应链重组，同时也会影响微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲
  • 亚太地区
  • 世界其他地区

第四章 竞赛

简介目录
Product Code: MCP12454

Global Human Papillomavirus (HPV) Testing Market to Reach US$1.8 Billion by 2030

The global market for Human Papillomavirus (HPV) Testing estimated at US$1.3 Billion in the year 2024, is expected to reach US$1.8 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Hospitals & Clinics End-Use, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$919.4 Million by the end of the analysis period. Growth in the Diagnostic Centers End-Use segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$352.7 Million While China is Forecast to Grow at 5.8% CAGR

The Human Papillomavirus (HPV) Testing market in the U.S. is estimated at US$352.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$284.5 Million by the year 2030 trailing a CAGR of 5.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.8% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Human Papillomavirus (HPV) Testing Market - Key Trends and Drivers Summarized

Is Human Papillomavirus (HPV) Testing the Key to Preventing Cervical Cancer and Improving Women's Health?

Human papillomavirus (HPV) testing has become a cornerstone of women’s health initiatives, but why is it so essential for preventing cervical cancer and improving overall healthcare outcomes? HPV is the most common sexually transmitted infection worldwide, and certain strains of the virus are directly linked to the development of cervical cancer, as well as other cancers such as those affecting the throat, anus, and genital areas. HPV testing identifies the presence of high-risk HPV strains that can cause these cancers, enabling earlier diagnosis and treatment.

The significance of HPV testing lies in its ability to detect high-risk infections long before cancerous changes occur in the cells. Early detection through HPV testing can prevent the development of cervical cancer by identifying those at risk and guiding timely intervention, such as further diagnostic procedures or preventive measures like vaccines. In combination with regular screening via Pap smears, HPV testing plays a critical role in reducing cervical cancer rates and improving women’s health. As awareness of HPV's role in cancer grows, widespread HPV testing has become a key public health measure in preventing serious outcomes related to this virus.

How Has Technology Advanced Human Papillomavirus (HPV) Testing?

Technological advancements have significantly improved the sensitivity, accuracy, and accessibility of HPV testing, making it a more effective tool for cancer prevention and screening. One of the most important developments is the introduction of molecular diagnostic techniques, such as polymerase chain reaction (PCR) testing, which can detect HPV DNA with high precision. PCR-based tests are able to identify the specific strains of HPV that are present, allowing clinicians to differentiate between high-risk and low-risk strains. This level of specificity enables more accurate risk assessment and ensures that individuals with high-risk infections receive appropriate follow-up care.

The integration of automated testing systems has also streamlined the process of HPV testing, reducing the potential for human error and improving efficiency in clinical settings. Automated platforms can process large volumes of samples quickly and consistently, making it easier for healthcare providers to incorporate HPV testing into routine screening programs. These advancements have also made HPV testing more accessible in low-resource settings, where manual processing might be less feasible.

Co-testing, which combines HPV testing with traditional Pap smears (cytology), has emerged as an effective strategy for cervical cancer screening. Co-testing allows healthcare providers to simultaneously screen for abnormal cervical cells and the presence of high-risk HPV strains, improving the accuracy of screening programs. This dual approach has been shown to increase the detection of precancerous changes in the cervix, ensuring that women at risk for cervical cancer are identified earlier.

Another significant technological advancement is the development of self-sampling HPV tests, which allow individuals to collect their own samples at home. Self-sampling kits contain instructions and tools for collecting a vaginal swab, which can then be sent to a lab for analysis. This innovation improves access to HPV testing, particularly for individuals who may face barriers to traditional healthcare settings, such as those living in remote areas or those who are uncomfortable with clinical exams. Research has shown that self-sampling tests are nearly as accurate as clinician-collected samples, making them a promising tool for increasing HPV screening coverage.

Advances in digital health tools have also played a role in improving HPV testing. Mobile apps and online platforms can help individuals track their screening schedules, receive test results, and access educational resources about HPV and cervical cancer prevention. These digital tools enhance patient engagement, making it easier for individuals to stay informed and proactive about their health.

Liquid-based cytology (LBC) is another improvement in HPV testing. Unlike traditional Pap smears, which rely on a slide sample, LBC suspends cells in liquid, providing a more comprehensive and clear sample for testing. This method not only allows for more accurate detection of abnormal cells but also enables the same sample to be tested for HPV, offering a streamlined approach to screening. LBC has been widely adopted in cervical cancer screening programs, helping to reduce false-negative results and ensuring that women with HPV-related abnormalities are identified early.

Why Is Human Papillomavirus (HPV) Testing Critical for Cervical Cancer Prevention and Public Health?

HPV testing is critical for cervical cancer prevention because it allows for the early detection of high-risk HPV infections, which are the leading cause of cervical cancer. By identifying individuals with these infections before any cancerous or precancerous changes occur in the cervix, HPV testing provides an opportunity for early intervention, such as increased monitoring, follow-up testing, or treatment of abnormal cells. This early detection is essential for reducing the incidence of cervical cancer, which remains one of the most preventable cancers with proper screening and vaccination.

Cervical cancer develops slowly over time, often starting with precancerous changes in the cells of the cervix. HPV testing can detect the presence of high-risk strains of the virus that are most likely to lead to these changes, even before visible abnormalities are detected on a Pap smear. This allows healthcare providers to monitor at-risk individuals more closely, reducing the chances of cervical cancer developing unnoticed. For women aged 30 and older, HPV testing is especially critical, as persistent HPV infections are more likely to cause cervical cancer in this age group.

HPV testing is also essential for public health because it can help reduce the overall burden of HPV-related cancers. Beyond cervical cancer, high-risk HPV strains are associated with other types of cancers, including anal, oropharyngeal (throat), and penile cancers. While cervical cancer screening is the most well-established use of HPV testing, research is ongoing to explore how HPV testing can be applied to other types of cancer screenings, particularly in populations at high risk.

The role of HPV testing in preventive care extends beyond diagnosis. HPV testing also plays a crucial role in guiding vaccination efforts. The introduction of the HPV vaccine has dramatically reduced the rates of high-risk HPV infections and cervical cancer in vaccinated populations. However, because not everyone receives the vaccine, and it is most effective when administered before exposure to HPV, regular testing remains necessary to catch infections that occur in unvaccinated or partially vaccinated individuals. HPV testing can help determine whether individuals are infected with high-risk strains even after vaccination, ensuring that they receive the necessary follow-up care.

The integration of HPV testing with broader cervical cancer screening programs has improved the effectiveness of preventive care worldwide. In many countries, cervical cancer remains a leading cause of death among women, particularly in regions with limited access to healthcare. HPV testing offers a more sensitive and reliable method for detecting precancerous changes than Pap smears alone, helping to identify high-risk individuals in low-resource settings. The use of self-sampling HPV tests further enhances access to screening by removing the need for in-person clinical visits, which can be a barrier in rural or underserved communities.

For men, while routine HPV testing is not as widespread, it is becoming more recognized in populations at high risk for HPV-related cancers, such as men who have sex with men (MSM). HPV testing is increasingly used to screen for anal cancer in these groups, where HPV infections are a significant risk factor. By expanding HPV testing beyond women, healthcare systems can further reduce the incidence of HPV-related cancers across all populations.

What Factors Are Driving the Growth of the Human Papillomavirus (HPV) Testing Market?

Several factors are driving the growth of the HPV testing market, including the rising prevalence of HPV infections, increased awareness of cervical cancer prevention, and advancements in testing technologies. One of the primary drivers is the growing recognition of the importance of early detection in preventing HPV-related cancers. As public health campaigns continue to emphasize the benefits of regular screening and vaccination, more individuals are seeking out HPV testing as part of their routine healthcare. This has led to increased demand for HPV testing services, particularly in countries with established cervical cancer screening programs.

The global expansion of vaccination programs, particularly for the HPV vaccine, is also driving market growth. As vaccination coverage increases, HPV testing remains crucial for monitoring the long-term effectiveness of vaccines and identifying infections in unvaccinated or partially vaccinated populations. In countries where HPV vaccination programs are being implemented, HPV testing is playing an essential role in tracking the impact of the vaccine on HPV infection rates and guiding public health policies.

Technological advancements in HPV testing have made these tests more accurate, accessible, and efficient, further boosting market demand. Innovations such as PCR-based tests, automated testing platforms, and self-sampling kits have made HPV testing more convenient and reliable, increasing uptake in both clinical and home settings. The development of self-sampling HPV tests, in particular, has expanded access to screening, especially in underserved communities, and is expected to continue driving growth in the market as more countries adopt these methods.

Government initiatives and public health programs aimed at reducing cervical cancer rates are another significant driver. In many regions, healthcare systems are shifting from traditional Pap smears to HPV testing as the primary method of cervical cancer screening, reflecting the superior sensitivity of HPV tests in detecting high-risk infections. The adoption of HPV primary screening in national screening programs is expected to increase significantly, particularly in countries with well-developed healthcare systems, driving further growth in the market.

Rising demand for personalized healthcare is also influencing the growth of the HPV testing market. As precision medicine becomes more prominent, there is growing interest in personalized screening and prevention strategies that take into account an individual’s unique risk factors. HPV testing offers a more individualized approach to cervical cancer screening by identifying those at highest risk and tailoring follow-up care accordingly. This trend is likely to continue as healthcare systems shift toward more personalized models of care, where tests like HPV screening play a crucial role in disease prevention.

The increasing prevalence of HPV-related cancers beyond cervical cancer is another factor driving market growth. While cervical cancer is the primary focus of HPV testing, the virus is also responsible for other cancers, including anal, oropharyngeal, and penile cancers. As awareness of these HPV-related cancers grows, particularly in high-risk populations, demand for HPV testing is expected to expand beyond traditional cervical cancer screening, creating new opportunities for growth in the market.

With advancements in technology, growing public health awareness, and the integration of HPV testing into national screening programs, the HPV testing market is poised for continued expansion. As healthcare systems increasingly prioritize early detection and preventive care, HPV testing will remain a critical tool for reducing the incidence of HPV-related cancers and improving health outcomes worldwide.

SCOPE OF STUDY:

The report analyzes the Human Papillomavirus (HPV) Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

End-Use (Hospitals & Clinics, Diagnostic Centers, Research Institutes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 46 Featured) -

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Arbor Vita Corporation
  • Becton, Dickinson & Company
  • Cepheid, Inc.
  • Daan Gene Co., Ltd.
  • Diagcor Bioscience Incorporation Ltd.
  • Enzo Biochem, Inc.
  • F. Hoffmann-La Roche AG
  • Fujirebio US, Inc.
  • Greiner Bio-One International GmbH
  • Hologic, Inc.
  • Hybribio Limited
  • Medical & Biological Laboratories Co. Ltd.
  • Norgen Biotek Corporation
  • Promega Corporation
  • Qiagen NV
  • Seegene, Inc.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • Zytovision GmbH

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Global Economic Update
    • Human Papillomavirus (HPV) Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Cervical Cancer Prevention Drives Growth in Human Papillomavirus (HPV) Testing Market
    • Expansion of HPV Vaccination Programs Spurs Adoption of HPV Testing in Screening Initiatives
    • Role of HPV Testing in Enhancing Early Detection and Cancer Prevention Strengthens Business Case for Adoption
    • Increasing Focus on Point-of-care HPV Testing and Self-sampling Kits Fuels Market Demand
    • Growth in Use of HPV Testing for Other Cancers, Including Anal and Oropharyngeal, Expands Market Opportunities
    • Growth in Demand for Co-testing (HPV and Cytology) in Cervical Cancer Screening Fuels Adoption
    • Technological Advancements in Liquid-based Cytology and Multiplex Testing Drive Market Innovation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Human Papillomavirus (HPV) Testing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Human Papillomavirus (HPV) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Human Papillomavirus (HPV) Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Human Papillomavirus (HPV) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: USA 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: Canada 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • JAPAN
    • Human Papillomavirus (HPV) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: Japan 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • CHINA
    • Human Papillomavirus (HPV) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: China 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • EUROPE
    • Human Papillomavirus (HPV) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Human Papillomavirus (HPV) Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Europe 15-Year Perspective for Human Papillomavirus (HPV) Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Europe 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • FRANCE
    • Human Papillomavirus (HPV) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: France 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • GERMANY
    • Human Papillomavirus (HPV) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Germany 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Italy 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Human Papillomavirus (HPV) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: UK 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Rest of Europe Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Rest of Europe 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Human Papillomavirus (HPV) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Asia-Pacific Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Asia-Pacific 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 50: Rest of World Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Rest of World Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Rest of World 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030

IV. COMPETITION